| Institute for Research & Innovation |
Multiple Sclerosis - Relapse (Ages 18-45)
Title: A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patient”Purpose: This study is seeking patients who have documented diagnoses of Relapsing Multiple Sclerosis
Who Can Participate? Patients who are being prescribed Tysabri as part of their regular care and have not taken any other MS modifying medications for more than 6 months prior to starting Tysabri.
Diagnosis or Condition: Patients with a clinical diagnosis of Multiple Sclerosis
Medication: Tysabri is delivered via IV infusion once monthly.
(Note: This study will not pay for Tysabri treatment.)
Age: Between 18 and 45 years of age
Sex: Males and Females
Visits: The study will involve up to 10 clinic visits and participation will last for up to 48 months
Stipend: You will be compensated for your time and travel
Principal Investigator(s): John Huddlestone, MD, FAAN
Study Coordinator: Andrea Thompson, 253-403-7440